B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy
Authors:
- 11 June 2021
- journal article
- research article
- Published by Wiley in Immunology
- Vol. 164 (3) , 507-523
Abstract
Loss of the B2M gene is associated with tumour immune escape and resistance to immunotherapy. However, genetic alterations of the B2M gene are rare. We performed an integrative analysis of the mutational and transcriptional profiles of large cohorts of non‐small‐cell lung cancer (NSCLC) patients and found that epigenetic downregulation of B2M is common. B2M‐low tumours exhibit a suppressive immune microenvironment characterized by reduced infiltration of immune cells of various lineages; in B2M‐high tumours, more T and natural killer cells are present, but their activities are constrained by immune checkpoint molecules, indicating the diverse mechanisms of immune evasion. High levels of B2M mRNA, but not PD‐L1, are correlated with an enhanced response to PD‐1‐based immunotherapy, suggesting its value for immunotherapy response prediction in solid tumours. Notably, a high tumour mutation burden (TMB) is associated with low B2M expression, which may explain the poor predictive value of the TMB in some situations. In syngeneic mouse models, genetic ablation of B2M in tumour cells causes resistance to PD‐1‐based immunotherapy, and B2M knockdown also diminishes the therapeutic efficacy. Moreover, forced expression of B2M in tumour models improves the response to immunotherapy, suggesting that B2M levels have significant impacts on treatment outcomes. Finally, we provide insight into the roles of transcription factors and KRAS mutations in B2M expression and the anticancer immune response. In conclusion, genetic and epigenetic regulation of B2M fundamentally shapes the NSCLC immune microenvironment and may determine the response to checkpoint blockade‐based immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (81771681)
This publication has 71 references indexed in Scilit:
- Inhibition of mitogen‐activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD‐L1‐upregulation in contrast to interferon‐γ treatmentCancer Science, 2014
- Enhancement of T cell recruitment and infiltration into tumoursClinical and Experimental Immunology, 2014
- IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue SamplesPLOS ONE, 2014
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activationJournal of Experimental Medicine, 2014
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- NLRC5, at the Heart of Antigen PresentationFrontiers in Immunology, 2013
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- Molecular Mechanisms of IFN-γ to Up-Regulate MHC Class I Antigen Processing and PresentationInternational Reviews of Immunology, 2009
- Localization of IFN- γ -Activated Stat1 and IFN Regulatory Factors 1 and 2 in Breast Cancer CellsJournal of Interferon & Cytokine Research, 2003
- IFN-γ-Induced MHC Class II Expression: Transactivation of Class II Transactivator Promoter IV by IFN Regulatory Factor-1 is Regulated by Protein Kinase C-αThe Journal of Immunology, 2003